drug: selegiline
- Clinical class: Anti-Parkinsonian; anti-depressant
- Action: Monoamine Oxidase Inhibitors (MAOI)
- Chemical class: levorotatory acetylenic derivative of phenethylamine
- CSA schedule: none
- DEA number: none
- Also: l-deprenyl
- MEDLINEplus® Drug Information
U.S. Preparations:
- Eldepril® (Somerset) FDA approved:
5.15.1996 for treatment of Parkinson's Disease as an adjunct to levodopa/carbidopa - Emsam® (Somerset) FDA approved:
2.27.2006 for treatment of depression
U.S. Prescribing information
- Selegiline HCl Tablets, USP (Apotex)
- Selegiline HCl Tablets, USP (Endo
Pharmaceuticals Inc.) FDA approved:
for treatment of Parkinson's Disease as an adjunct to levodopa/carbidopa
U.S. Prescribing information - Zelapar®
orally disintegrating tablets (Valeant) FDA approved:
6.14.2006 as an adjunct in the management of patients with Parkinson's Disease being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy.
U.S. Prescribing information
Preparations Outside U.S.:
- Ambo-neural, Amboneural, Amindan, Antiparkin, Cognitiv, Cosmopril, Deprenyl, Deprilan, Egibren, Julap, Jumex, Jumexal, Kinabide, Movergan, Moverin, Novo-Selegine, Parkinyl, Plurimen, Procythol, Regepar, Seledat, Selegam, Selegiline, Selepar, Selepark, Selepark, Seletop, Selgene, Selpar, Sepatrem, Tremorex, Vivapryl, Zelapon